Telo Genomics (TSXV:TELO) 3-Year EPS without NRI Growth Rate : -18.60% (As of Sep. 2024)

View and export this data going back to 2012. Start your Free Trial

What is Telo Genomics 3-Year EPS without NRI Growth Rate?

Telo Genomics's EPS without NRI for the three months ended in Sep. 2024 was C$-0.01.

During the past 3 years, the average EPS without NRI Growth Rate was -18.60% per year. During the past 5 years, the average EPS without NRI Growth Rate was 6.30% per year. During the past 10 years, the average EPS without NRI Growth Rate was 16.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Telo Genomics was 65.70% per year. The lowest was -114.50% per year. And the median was 7.20% per year.

Competitive Comparison of Telo Genomics's 3-Year EPS without NRI Growth Rate

For the Diagnostics & Research subindustry, Telo Genomics's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Telo Genomics's 3-Year EPS without NRI Growth Rate Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Telo Genomics's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Telo Genomics's 3-Year EPS without NRI Growth Rate falls into.

Telo Genomics 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

Telo Genomics (TSXV:TELO) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.

Telo Genomics 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Telo Genomics's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Telo Genomics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Telo Genomics Corp (TSXV:TELO) » Definitions » 3-Year EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

TDSGF:USA

Address

101 College Street, Suite 200, MaRS Centre, South Tower, Toronto, ON, CAN, M5G 1L7

Website

https://www.telodx.com

Telo Genomics Corp is a personalized medicine company. The company through its wholly-owned subsidiary is engaged in developing diagnostic and prognostic products that may save lives, improve the quality of life, and reduce the cost of care associated with numerous diseases that display genomic instability. The company has a single operating segment, focused on the development and commercialization of predictive technological products designed to personalize treatment plans for patients who have specific conditions.

Executives